Simulations Plus invests $1 million in clinical trial technology firm Nurocor
/Simulations Plus, Inc. (NASDAQ: SLP) announced an investment of $1 million in clinical development technology company Nurocor, according to a press release statement.
The investment was made through Simulations Plus' Corporate Development Initiative, which launched in 2024 to support early-stage technology companies in the pharmaceutical industry.
Founded in 2017, Nurocor operates a cloud-based software platform designed to improve efficiency and automation for pharmaceutical companies during clinical development phases. The company's solution aims to accelerate clinical trial lifecycles and reduce overall development costs.
"We are pleased to support Nurocor in its mission to help clients leverage technology to bring drugs to market more rapidly," said Shawn O'Connor, Chief Executive Officer of Simulations Plus. "Their vision aligns with our own, and we see tremendous potential for clients to deploy our complementary solutions in clinical trial design, protocol development, and site competency and compliance."